ORPP logo
Image from Google Jackets

Current Studies in HIV Research : Current Studies in HIV Research.

By: Material type: TextTextSeries: Frontiers in HIV Research SeriesPublisher: Sharjah : Bentham Science Publishers, 2016Copyright date: ©2016Edition: 1st edDescription: 1 online resource (355 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781681082554
Subject(s): Genre/Form: Additional physical formats: Print version:: Current Studies in HIV ResearchDDC classification:
  • 362.1969792
LOC classification:
  • RA643.8 .F766 2016
Online resources:
Contents:
Intro -- CONTENTS -- FOREWORD -- PREFACE -- List of Contributors -- Diversity and Global Epidemiology of HIV -- 1. INTRODUCTION -- 2. HIV GENETIC DIVERSITY -- 3. GLOBAL DISTRIBUTION -- 4. THE IMPACT OF HIV DIVERSITY -- 4.1. The Impact of HIV Diversity on Pathogenesis -- 4.2. The Impact of HIV Diversity on Disease Progression and Transmission -- 4.3. The Impact of HIV Diversity on Response to HAART and Drug Resistance -- 4.4. HIV Diversity and HIV Vaccines -- 5. THE GLOBAL EPIDEMIC AT A GLANCE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Transmission -- 1. INTRODUCTION -- 2. SEXUAL TRANSMISSION OF HIV -- 2.1. Anal Intercourse -- 2.2. Vaginal Intercourse -- 2.3. Oral Intercourse -- 3. FACTORS AFFECTING SEXUAL TRANSMISSIBILITY OF HIV -- 4. HIV TRANSMISSION AMONG PEOPLE WHO USE DRUGS -- 4.1. Risk per Drug Injection -- 5. MOTHER-TO-CHILD TRANSMISSION OF HIV -- 5.1. Factors Affecting Mother to Child HIV Transmission -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Mother-to-Child Transmission of HIV Infection: Timing, Risk Factors and Strategies for Prevention -- 1. INTRODUCTION -- 2. THE TIMING AND RISKS OF MOTHER-TO-CHILD HIV TRANSMISSION -- 2.1. HIV Transmission In Utero -- 2.2. HIV Transmission During Delivery -- 2.3. HIV Transmission During Breast Feeding -- 3. RISK FACTORS FOR HIV TRANSMISSION FROM MOTHER TO CHILD -- 3.1. Risk Factors for In Utero Transmission -- 3.2. Risk Factors for Peripartum Transmission -- 3.3. Risk Factors during Breast Feeding -- 3.4. Risk Factors That Have Not Been Assigned to a Particular Time of Transmission -- 4. THE IMPORTANCE OF ANTIVIRAL TREATMENT IN MOTHER-TO- CHILD TRANSMISSION OF HIV -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Reducing Pre-partum and Intra-partum Transmission of HIV to Infants -- 1. INTRODUCTION -- 2. PREVENTING MOTHER TO CHILD TRANSMISSION (PMTCT).
3. THE DIAGNOSTIC TESTS FOR HIV INFECTION IN INFANTS AND CHILDREN -- 4. PRENATAL CARE -- 4.1. Antiretroviral Therapy in Reducing Perinatal Transmission of HIV -- 4.2. HIV Counseling -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Infection and Cell Signaling Pathways -- 1. INTRODUCTION -- 2. SIGNALING PATHWAYS THAT ARE ACTIVATED VIA HIV GP120 AND CHEMOKINE CO-RECEPTORS -- 3. THE ROLE OF HIV REGULATORY AND ACCESSORY PROTEINS ON CELLULAR SIGNALING PATHWAYS -- 3.1. The Role of HIV Nef Protein -- 3.2. The Role of NF- κB Transcription Factors and Tat -- 3.3. The Role of Vpr -- 4. DNA DAMAGE-SIGNALING PATHWAYS AND APOPTOSIS IN HIV INFECTION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Determinants of HIV Pathogenesis Related to Disease Progression -- 1. INTRODUCTION -- 2. DETERMINANTS OF HIV PATHOGENESIS -- 2.1. Host Genetic -- A. Genes Encoding Cell-surface Receptors or their Ligands -- B. Genes within Human Leukocyte Antigens (HLA) that Regulate Host Immune Responses to Infection -- 2.2. Cytokines and Immune Cell Responses -- 2.3. The Role of NK Cell and Dendritic Cells -- 2.4. Chronic Immune Activation -- 2.5. Intrinsic Intracellular Factors -- 2.6. Other Factors Related to Host -- 3. VIRUS DETERMINANTS -- 3.1. HIV-1 Evolution -- 3.2. CD4+ T cell Depletion -- 4. THE EFFECT OF CO-INFECTIONS ON PROGRESSION RATES -- CONCLUDING REMARKS AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Systems Biology -- 1. INTRODUCTION -- 2. HIV-1-HUMAN PROTEIN INTERACTION NETWORK -- 3. MICRORNAS AND HIV-1: COMPLEX INTERACTIONS -- 4. EPIGENETIC REGULATION OF HIV-1 LATENCY -- 5. SYSTEMATIC PROFILING OF IMMUNE SYSTEM IN HIV INFECTION -- 6. THE BEST APPROACH TO STUDY HIV INFECTION BY SYSTEM BIOLOGY.
7. AN ANIMAL MODEL FOR STUDYING HIV INFECTION BY SYSTEM BIOLOGY: NON-HUMAN PRIMATE MODELS OF SIV INFECTION -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV/TB Co-Infection -- 1. INTRODUCTION -- 2. INTERACTION OF TB AND HIV -- 2.1. The Effect of HIV Infection on Active Tuberculosis -- 2.2. The Effect of HIV Infection on Tuberculosis Transmission -- 2.3. The Effect of HIV Infection on Tuberculosis Symptoms -- 2.4. The Effect of Tuberculosis on HIV Infection -- 3. CLINICAL SIGNS AND SYMPTOMS -- 4. DIAGNOSIS -- 4.1. Diagnosis of LTB -- 4.2. Diagnosis of Active Tuberculosis -- Gen Xpert MTB/RIF -- TB-LAM Assay -- 5. TREATMENTS -- 5.1. Treatment of LTB -- 5.2. Treatment of Active Tuberculosis -- 5.3. Simultaneous Treatment of HIV and TB -- Co-trimoxazole -- 5.4. Tuberculosis Immune Reconstitution Syndrome (IRIS) -- 5.5. Prophylaxis from Exposure to Mycobacterium Tuberculosis -- 5.6. BCG Vaccination -- A Few Tips -- Diabetes Mellitus with HIV/TB Co-infection: -- HIV/TB with Alcoholism: -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV and Hepatitis Viruses Co-infection: A Closer View of Their Interactions and Clinical Consequences -- 1. INTRODUCTION -- 2. THE CLINICAL SIGNIFICANCE OF CO-INFECTION WITH HIV AND HEPATITIS-RELATED VIRUSES -- 3. COMMON SITE OF REPLICATION: A BACKYARD FOR CLOSE INTERACTIONS? -- 4. NEUROTOXIC EFFECTS ASSOCIATED WITH HIV/HEPATITIS-RELATED VIRUSES CO-INFECTION -- 5. HIV INFECTION AND HEPATIC PATHOGENESIS -- 6. STELLATE CELLS CO-INFECTION: UNDERSTANDING THE HIV-INDUCED LIVER FIBROSIS -- 7. DIRECT INTERACTIONS BETWEEN VIRAL REPLICATION CYCLES -- 8. ON THE IMPORTANCE OF APOPTOSIS -- 9. THE ROLE OF MIRNAS IN HIV/HEPATITIS RELATED VIRUSES CO-INFECTION -- 10. IMMUNE MODULATION -- 11. CLINICAL MANAGEMENT OF HIV/HEPATITIS CO-INFECTION -- 12. CONCLUDING REMARKS AND FUTURE PERSPECTIVES.
CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Testing for HIV Infection -- 1. INTRODUCTION -- 2. STAGES OF THE ACUTE PRIMARY HIV INFECTION: IMPLICATIONS FOR HIV TESTING -- 3. THE INITIAL DIAGNOSTIC TEST FOR HIV INFECTION -- 3.1. Rapid Diagnostic Tests -- 3.2. Enzyme-linked Immunosorbent Assay (ELISA) -- 4. SUPPLEMENTARY TESTS FOR HIV INFECTION -- 4.1. Western Blot -- 4.2. Indirect Immunofluorescence Assay (IFA) -- 4.3. Polymerase Chain Reaction (PCR) -- 5. HIV TEST RESULTS -- 6. CD4 T CELL COUNT -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- When to Start Antiretroviral Therapy -- 1. INTRODUCTION -- 2. EVIDENCES IN FAVOR OF EARLIER ART INITIATION -- 2.1. Evidences from Clinical Trials -- 2.2. Effect of Viral Dynamics -- 2.3. Effect of Inflammation on Body Organs -- 2.4. Newer Medications are Better Tolerated -- 2.5. Data from Cohort Studies -- 2.6. Public Health -- 3. CONCERNS ABOUT EARLY ART INITIATION -- 3.1. Effect of Long Term ART Toxicity -- 3.1.1. Effect of Early ART Initiation on Quality of Life -- 3.1.2. Impact of Possible ART Non-Adherence on Viral Resistance -- 3.1.3. Feasibility of Implementing Early ART -- 4. EVIDENCE-BASED TIMELY INITIATION OF ART -- 4.1. ART for Patients with a History of an AIDS-Defining Illness or CD4 Count &lt -- 350 Cells/mm3 -- 4.2. ART for HIV-Associated Nephropathy (HIVAN) -- 4.3. ART for Co-Infection with Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) -- 4.4. ART for Cardiovascular Diseases (CVD) -- 4.5. ART for Malignancies -- 4.6. ART for Neurological Diseases -- 4.7. ART and Aging -- 4.8. ART for Prevention of Perinatal Transmission -- 4.9. ART for Prevention of Sexual Transmission -- 4.10. ART During Acute HIV Infection -- 4.11. ART Among Children -- 4.12. ART for Elite Controller -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES.
Antiretroviral Therapy (ART) in Pregnant Women -- 1. INTRODUCTION -- 2. HISTORICAL OVERVIEW OF PMTCT -- 3. THE GUIDELINES IN PRACTICE -- 3.1. When to Start -- 3.2. What to Start: Programmatic Options for PMTCT Care -- 3.3. ARVs in Special Populations of Pregnant Women -- 3.3.1. Hepatitis B Virus Co-Infection -- 3.3.2. Women with Active Tuberculosis Infection -- 4. INFANT ANTIRETROVIRAL PROPHYLAXIS -- 5. CHOICE OF ART REGIMEN FOR WOMEN WITH PRIOR EXPOSURE TO PMTCT PROPHYLAXIS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Drug Resistance -- 1. INTRODUCTION -- 2. GLOBAL EPIDEMIOLOGY OF TRANSMITTED DRUG RESISTANCE -- 2.1. TDR in The USA -- 2.2. TDR in Latin America -- 2.3. TDR in Europe -- 2.4. TDR in Africa &amp -- Asia -- 2.5. TDR in Non-B Subtypes -- Conclusion -- 3. DETERMINANTS OF HIV DRUG RESISTANCE -- 3.1. Viral Determinants of Drug Resistance -- 3.2. Host Factors -- 4. MECHANISMS OF ANTI-RETROVIRAL DRUG RESISTANCE -- 4.1. Resistance to Nucleoside and Nucleotide Analogues -- 4.2. Resistance to NNRTIs -- 4.3. Resistance to PIs -- 4.4. Resistance to Fusion Inhibitors -- 5. GUIDELINES FOR TREATMENT OF FIRST-LINE TREATMENT RESISTANT INFECTIONS -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Serodiscordant Couples and Fertility Management -- 1. INTRODUCTION -- 2. INSEMINATION OF HIV NEGATIVE WOMEN WITH PROCESSED SEMEN OF HIV POSITIVE PARTNERS -- 3. HIV STATUS IN DISCORDANT COUPLES -- 4. HIV-1 SUBTYPES PATHOGENICITY IN HETEROSEXUAL COUPLES -- 5. NEW CASES OF HIV POSITIVE PATIENTS IN MARRIED OR COHABITING COUPLES -- 6. RATE OF HIV TRANSMISSION PER COITAL ACT -- 7. PREVENTING ROUTES -- 7.1. Condom Use -- 7.2. Male Circumcision -- 7.3. Voluntary Counseling and Testing (VCT) for Couples -- 7.4. Serodiscordant Couples Behavior and Attitude -- 8. PRE EXPOSURE PROPHYLAXIS (PREP) FOR A SAFE CONCEPTION.
9. ANTIVIRAL AGENTS' EFFECTIVENESS (PARTNERSHIP INTERVENTIONS).
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Intro -- CONTENTS -- FOREWORD -- PREFACE -- List of Contributors -- Diversity and Global Epidemiology of HIV -- 1. INTRODUCTION -- 2. HIV GENETIC DIVERSITY -- 3. GLOBAL DISTRIBUTION -- 4. THE IMPACT OF HIV DIVERSITY -- 4.1. The Impact of HIV Diversity on Pathogenesis -- 4.2. The Impact of HIV Diversity on Disease Progression and Transmission -- 4.3. The Impact of HIV Diversity on Response to HAART and Drug Resistance -- 4.4. HIV Diversity and HIV Vaccines -- 5. THE GLOBAL EPIDEMIC AT A GLANCE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Transmission -- 1. INTRODUCTION -- 2. SEXUAL TRANSMISSION OF HIV -- 2.1. Anal Intercourse -- 2.2. Vaginal Intercourse -- 2.3. Oral Intercourse -- 3. FACTORS AFFECTING SEXUAL TRANSMISSIBILITY OF HIV -- 4. HIV TRANSMISSION AMONG PEOPLE WHO USE DRUGS -- 4.1. Risk per Drug Injection -- 5. MOTHER-TO-CHILD TRANSMISSION OF HIV -- 5.1. Factors Affecting Mother to Child HIV Transmission -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Mother-to-Child Transmission of HIV Infection: Timing, Risk Factors and Strategies for Prevention -- 1. INTRODUCTION -- 2. THE TIMING AND RISKS OF MOTHER-TO-CHILD HIV TRANSMISSION -- 2.1. HIV Transmission In Utero -- 2.2. HIV Transmission During Delivery -- 2.3. HIV Transmission During Breast Feeding -- 3. RISK FACTORS FOR HIV TRANSMISSION FROM MOTHER TO CHILD -- 3.1. Risk Factors for In Utero Transmission -- 3.2. Risk Factors for Peripartum Transmission -- 3.3. Risk Factors during Breast Feeding -- 3.4. Risk Factors That Have Not Been Assigned to a Particular Time of Transmission -- 4. THE IMPORTANCE OF ANTIVIRAL TREATMENT IN MOTHER-TO- CHILD TRANSMISSION OF HIV -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Reducing Pre-partum and Intra-partum Transmission of HIV to Infants -- 1. INTRODUCTION -- 2. PREVENTING MOTHER TO CHILD TRANSMISSION (PMTCT).

3. THE DIAGNOSTIC TESTS FOR HIV INFECTION IN INFANTS AND CHILDREN -- 4. PRENATAL CARE -- 4.1. Antiretroviral Therapy in Reducing Perinatal Transmission of HIV -- 4.2. HIV Counseling -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Infection and Cell Signaling Pathways -- 1. INTRODUCTION -- 2. SIGNALING PATHWAYS THAT ARE ACTIVATED VIA HIV GP120 AND CHEMOKINE CO-RECEPTORS -- 3. THE ROLE OF HIV REGULATORY AND ACCESSORY PROTEINS ON CELLULAR SIGNALING PATHWAYS -- 3.1. The Role of HIV Nef Protein -- 3.2. The Role of NF- κB Transcription Factors and Tat -- 3.3. The Role of Vpr -- 4. DNA DAMAGE-SIGNALING PATHWAYS AND APOPTOSIS IN HIV INFECTION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Determinants of HIV Pathogenesis Related to Disease Progression -- 1. INTRODUCTION -- 2. DETERMINANTS OF HIV PATHOGENESIS -- 2.1. Host Genetic -- A. Genes Encoding Cell-surface Receptors or their Ligands -- B. Genes within Human Leukocyte Antigens (HLA) that Regulate Host Immune Responses to Infection -- 2.2. Cytokines and Immune Cell Responses -- 2.3. The Role of NK Cell and Dendritic Cells -- 2.4. Chronic Immune Activation -- 2.5. Intrinsic Intracellular Factors -- 2.6. Other Factors Related to Host -- 3. VIRUS DETERMINANTS -- 3.1. HIV-1 Evolution -- 3.2. CD4+ T cell Depletion -- 4. THE EFFECT OF CO-INFECTIONS ON PROGRESSION RATES -- CONCLUDING REMARKS AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Systems Biology -- 1. INTRODUCTION -- 2. HIV-1-HUMAN PROTEIN INTERACTION NETWORK -- 3. MICRORNAS AND HIV-1: COMPLEX INTERACTIONS -- 4. EPIGENETIC REGULATION OF HIV-1 LATENCY -- 5. SYSTEMATIC PROFILING OF IMMUNE SYSTEM IN HIV INFECTION -- 6. THE BEST APPROACH TO STUDY HIV INFECTION BY SYSTEM BIOLOGY.

7. AN ANIMAL MODEL FOR STUDYING HIV INFECTION BY SYSTEM BIOLOGY: NON-HUMAN PRIMATE MODELS OF SIV INFECTION -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV/TB Co-Infection -- 1. INTRODUCTION -- 2. INTERACTION OF TB AND HIV -- 2.1. The Effect of HIV Infection on Active Tuberculosis -- 2.2. The Effect of HIV Infection on Tuberculosis Transmission -- 2.3. The Effect of HIV Infection on Tuberculosis Symptoms -- 2.4. The Effect of Tuberculosis on HIV Infection -- 3. CLINICAL SIGNS AND SYMPTOMS -- 4. DIAGNOSIS -- 4.1. Diagnosis of LTB -- 4.2. Diagnosis of Active Tuberculosis -- Gen Xpert MTB/RIF -- TB-LAM Assay -- 5. TREATMENTS -- 5.1. Treatment of LTB -- 5.2. Treatment of Active Tuberculosis -- 5.3. Simultaneous Treatment of HIV and TB -- Co-trimoxazole -- 5.4. Tuberculosis Immune Reconstitution Syndrome (IRIS) -- 5.5. Prophylaxis from Exposure to Mycobacterium Tuberculosis -- 5.6. BCG Vaccination -- A Few Tips -- Diabetes Mellitus with HIV/TB Co-infection: -- HIV/TB with Alcoholism: -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV and Hepatitis Viruses Co-infection: A Closer View of Their Interactions and Clinical Consequences -- 1. INTRODUCTION -- 2. THE CLINICAL SIGNIFICANCE OF CO-INFECTION WITH HIV AND HEPATITIS-RELATED VIRUSES -- 3. COMMON SITE OF REPLICATION: A BACKYARD FOR CLOSE INTERACTIONS? -- 4. NEUROTOXIC EFFECTS ASSOCIATED WITH HIV/HEPATITIS-RELATED VIRUSES CO-INFECTION -- 5. HIV INFECTION AND HEPATIC PATHOGENESIS -- 6. STELLATE CELLS CO-INFECTION: UNDERSTANDING THE HIV-INDUCED LIVER FIBROSIS -- 7. DIRECT INTERACTIONS BETWEEN VIRAL REPLICATION CYCLES -- 8. ON THE IMPORTANCE OF APOPTOSIS -- 9. THE ROLE OF MIRNAS IN HIV/HEPATITIS RELATED VIRUSES CO-INFECTION -- 10. IMMUNE MODULATION -- 11. CLINICAL MANAGEMENT OF HIV/HEPATITIS CO-INFECTION -- 12. CONCLUDING REMARKS AND FUTURE PERSPECTIVES.

CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Testing for HIV Infection -- 1. INTRODUCTION -- 2. STAGES OF THE ACUTE PRIMARY HIV INFECTION: IMPLICATIONS FOR HIV TESTING -- 3. THE INITIAL DIAGNOSTIC TEST FOR HIV INFECTION -- 3.1. Rapid Diagnostic Tests -- 3.2. Enzyme-linked Immunosorbent Assay (ELISA) -- 4. SUPPLEMENTARY TESTS FOR HIV INFECTION -- 4.1. Western Blot -- 4.2. Indirect Immunofluorescence Assay (IFA) -- 4.3. Polymerase Chain Reaction (PCR) -- 5. HIV TEST RESULTS -- 6. CD4 T CELL COUNT -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- When to Start Antiretroviral Therapy -- 1. INTRODUCTION -- 2. EVIDENCES IN FAVOR OF EARLIER ART INITIATION -- 2.1. Evidences from Clinical Trials -- 2.2. Effect of Viral Dynamics -- 2.3. Effect of Inflammation on Body Organs -- 2.4. Newer Medications are Better Tolerated -- 2.5. Data from Cohort Studies -- 2.6. Public Health -- 3. CONCERNS ABOUT EARLY ART INITIATION -- 3.1. Effect of Long Term ART Toxicity -- 3.1.1. Effect of Early ART Initiation on Quality of Life -- 3.1.2. Impact of Possible ART Non-Adherence on Viral Resistance -- 3.1.3. Feasibility of Implementing Early ART -- 4. EVIDENCE-BASED TIMELY INITIATION OF ART -- 4.1. ART for Patients with a History of an AIDS-Defining Illness or CD4 Count &lt -- 350 Cells/mm3 -- 4.2. ART for HIV-Associated Nephropathy (HIVAN) -- 4.3. ART for Co-Infection with Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) -- 4.4. ART for Cardiovascular Diseases (CVD) -- 4.5. ART for Malignancies -- 4.6. ART for Neurological Diseases -- 4.7. ART and Aging -- 4.8. ART for Prevention of Perinatal Transmission -- 4.9. ART for Prevention of Sexual Transmission -- 4.10. ART During Acute HIV Infection -- 4.11. ART Among Children -- 4.12. ART for Elite Controller -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES.

Antiretroviral Therapy (ART) in Pregnant Women -- 1. INTRODUCTION -- 2. HISTORICAL OVERVIEW OF PMTCT -- 3. THE GUIDELINES IN PRACTICE -- 3.1. When to Start -- 3.2. What to Start: Programmatic Options for PMTCT Care -- 3.3. ARVs in Special Populations of Pregnant Women -- 3.3.1. Hepatitis B Virus Co-Infection -- 3.3.2. Women with Active Tuberculosis Infection -- 4. INFANT ANTIRETROVIRAL PROPHYLAXIS -- 5. CHOICE OF ART REGIMEN FOR WOMEN WITH PRIOR EXPOSURE TO PMTCT PROPHYLAXIS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- HIV Drug Resistance -- 1. INTRODUCTION -- 2. GLOBAL EPIDEMIOLOGY OF TRANSMITTED DRUG RESISTANCE -- 2.1. TDR in The USA -- 2.2. TDR in Latin America -- 2.3. TDR in Europe -- 2.4. TDR in Africa &amp -- Asia -- 2.5. TDR in Non-B Subtypes -- Conclusion -- 3. DETERMINANTS OF HIV DRUG RESISTANCE -- 3.1. Viral Determinants of Drug Resistance -- 3.2. Host Factors -- 4. MECHANISMS OF ANTI-RETROVIRAL DRUG RESISTANCE -- 4.1. Resistance to Nucleoside and Nucleotide Analogues -- 4.2. Resistance to NNRTIs -- 4.3. Resistance to PIs -- 4.4. Resistance to Fusion Inhibitors -- 5. GUIDELINES FOR TREATMENT OF FIRST-LINE TREATMENT RESISTANT INFECTIONS -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Serodiscordant Couples and Fertility Management -- 1. INTRODUCTION -- 2. INSEMINATION OF HIV NEGATIVE WOMEN WITH PROCESSED SEMEN OF HIV POSITIVE PARTNERS -- 3. HIV STATUS IN DISCORDANT COUPLES -- 4. HIV-1 SUBTYPES PATHOGENICITY IN HETEROSEXUAL COUPLES -- 5. NEW CASES OF HIV POSITIVE PATIENTS IN MARRIED OR COHABITING COUPLES -- 6. RATE OF HIV TRANSMISSION PER COITAL ACT -- 7. PREVENTING ROUTES -- 7.1. Condom Use -- 7.2. Male Circumcision -- 7.3. Voluntary Counseling and Testing (VCT) for Couples -- 7.4. Serodiscordant Couples Behavior and Attitude -- 8. PRE EXPOSURE PROPHYLAXIS (PREP) FOR A SAFE CONCEPTION.

9. ANTIVIRAL AGENTS' EFFECTIVENESS (PARTNERSHIP INTERVENTIONS).

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.